Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1619749

This article is part of the Research TopicMicrobiota-Immunity Dynamics in Cancer: Mechanisms and Implications for Treatment StrategiesView all 6 articles

Role of Necroptosis-Related Genes in Immune Activity and Prognosis of Colorectal Cancer

Provisionally accepted
Lulu TanLulu Tan1Shuaifeng WangShuaifeng Wang1Weilong ChangWeilong Chang1Xiaoying ZhangXiaoying Zhang2Rui DengRui Deng1Huifang YanHuifang Yan3Weiwei ZhuWeiwei Zhu1Huifen WangHuifen Wang1Yudie CaiYudie Cai1Zhibo LiuZhibo Liu1*Yuyan TanYuyan Tan2*Jinyuan CuiJinyuan Cui1*
  • 1First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2China Three Gorges University, Yichang, China
  • 3The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: Necroptosis plays a critical role in the onset and progression of numerous malignancies, with colorectal cancer (CRC) ranking among the leading causes of cancer-related mortality worldwide. However, the relationship between necroptosisrelated genes (NRGs) and CRC remains contentious. Hence, this study aims to develop a novel NRG-based signature to predict the prognosis of CRC patients and explore its potential role.Methods: Transcriptome data from the Gene Expression Omnibus (GEO) databases and the Cancer Genome Atlas (TCGA) were employed to identify cancer hallmarks associated with outcomes in CRC. A novel NRG signature was formulated and validated using least absolute shrinkage and selection operator (LASSO) regression analysis and COX regression analysis. Subsequently, univariate and multivariate Cox regression analyses, Kaplan-Meier (K-M) survival analysis, receiver operating characteristic (ROC) curves, and nomograms were utilized to assess the predictive capability of our signature. Furthermore, a variety of bioinformatics analysis algorithms were leveraged to uncover potential mechanisms, tumor immune status, and differences in drug sensitivity between the two-risk groups. The expression of signature NRGs in CRC was evaluated through quantitative reverse transcription polymerase chain reaction (qRT-PCR).

Keywords: Results: A novel signature consisting of eighteen NRGs (CTSB, PAEP, ARL4C, TAP2, WFS1, BATF2, DUSP27, CXCL9

Received: 28 Apr 2025; Accepted: 05 Aug 2025.

Copyright: © 2025 Tan, Wang, Chang, Zhang, Deng, Yan, Zhu, Wang, Cai, Liu, Tan and Cui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Zhibo Liu, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
Yuyan Tan, China Three Gorges University, Yichang, China
Jinyuan Cui, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material